<DOC>
	<DOCNO>NCT02128061</DOCNO>
	<brief_summary>The purpose study compare efficacy R2-miniCHOP ( Sub-cutaneous Rituximab-miniCHOP + lenalidomide ) R-miniCHOP ( Sub-cutaneous Rituximab-miniCHOP ) patient age 80 year old previously treat cluster differentiation antigen 20 positive ( CD20+ ) diffuse large B-cell lymphoma measure overall survival ( OS ) .The SENIOR trial evaluate tolerance efficacy combination R2-miniCHOP regimen compare experimental arm standard R-miniCHOP regimen.The statistical plan base hypothesis increase 15 % 2y-OS favor experimental arm , compare reference arm ( R-miniCHOP ) .</brief_summary>
	<brief_title>Efficacy Lenalidomide Combination With Subcutaneous Rituximab + miniCHOP DLBCL Patients 80 y/o or+</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patient histologically proven CD20+ diffuse large Bcell lymphoma ( DLBCL ) ( WHO classification 2008 ) include clinical subtypes ( primary mediastinal , intravascular , etc… ) , ageadjusted International Prognostic Index ( aaIPI ) . May also include : De Novo transform DLBCL low grade lymphoma ( Follicular , ... ) DLBCL associate small cell Infiltration bone marrow lymph node ; CD20+ Bcell lymphoma , intermediate feature DLBCL Burkitt intermediate feature DLBCL classical Hodgkin lymphoma ; CD20+ Follicular lymphoma grade 3B ( accord WHO classification ) ; CD20+ Aggressive Bcell lymphoma unclassifiable . With Cluster Differentiation antigen 10 ( CD10 ) immunostaining perform participate center pathologist Aged ≥ 80 year old Ann Arbor stage II , III IV Patient previously untreated DLBCL Lymphoma Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 With minimum life expectancy 3 month Negative HIV , hepatitis B virus ( HBV ) ( antihepatitis B core antigen ( HBc ) negativity ) hepatitis C virus ( HCV ) serologies test within 4 week inclusion ( except vaccination ) Patient able give consent sign write Informed consent Patient affiliate social security system , applicable Male patient must practice complete abstinence agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption , 3 month follow study drug discontinuation , even undergone successful vasectomy . All patient must agree fulfill global Lenalidomide Pregnancy Prevention Risk Management Plan applicable accord randomization arm ( randomization arm ) Any histological type lymphoma , Burkitt include Any history treat nontreated smallB cell lymphoma Central nervous system meningeal involvement lymphoma Contraindication drug contain chemotherapy regimen ; anthracycline use , ejection fraction &gt; 50 % Any serious active disease ( accord investigator 's decision ) History deep venous thrombosis arterial thromboembolism event within past 12 month inclusion Poor renal function ( creatinine clearance &lt; 40 ml/min , accord Modification Diet Renal Disease ( MDRD ) formula ) Poor hepatic function ( total bilirubin level &gt; 30mmol/l , transaminase &gt; 2.5 maximum normal level ) unless abnormality relate lymphoma Poor bone marrow reserve define neutrophil &lt; 1.5 G/l platelet &lt; 100 G/l , unless relate bone marrow infiltration Any history cancer last 5 year exception nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma Patients previously diagnose prostate cancer eligible ( 1 ) disease T1T2a , N0 , M0 , Gleason score ≤7 , prostate specific antigen ( PSA ) ≤10 ng/mL prior initial therapy , ( 2 ) definitive curative therapy ( i.e. , prostatectomy radiotherapy ) 2 year Day 1 Cycle 1 , ( 3 ) minimum 2 year follow therapy clinical evidence prostate cancer , PSA undetectable underwent prostatectomy &lt; 1 ng/mL undergo prostatectomy Treatment investigational drug within 30 day plan first cycle chemotherapy study Prior treatment antiCD20 monoclonal antibody alemtuzumab within 3 month prior start therapy Prior use lenalidomide Prior ≥ Grade 3 allergic reaction/hypersensitivity thalidomide Prior ≥ Grade 3 rash desquamating ( blister ) rash take thalidomide Subjects ≥ Grade 2 neuropathy Adult patient tutelage Female childbearing potential exclude . ( Note : Females define childbearing potential documentation `` natural menopause least 24 consecutive month , hysterectomy bilateral oophorectomy '' )</criteria>
	<gender>All</gender>
	<minimum_age>80 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>